24,379 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, Holdings Channel.com reports. The fund acquired 24,379 shares of the company’s stock, valued at approximately $16,497,000.

A number of other institutional investors have also added to or reduced their stakes in IDXX. Empowered Funds LLC lifted its holdings in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter worth about $265,000. Jump Financial LLC lifted its holdings in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after purchasing an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter worth about $164,000. Finally, Sei Investments Co. lifted its holdings in IDEXX Laboratories by 218.7% during the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after purchasing an additional 82,755 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IDXX. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $563.53 on Monday. The firm has a market capitalization of $44.45 billion, a P/E ratio of 41.50, a P/E/G ratio of 3.27 and a beta of 1.56. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock’s 50-day simple moving average is $564.58 and its two-hundred day simple moving average is $636.68. IDEXX Laboratories, Inc. has a twelve month low of $504.56 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president directly owned 18,141 shares in the company, valued at $11,511,734.37. This represents a 8.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.